ADMA vs JAZZ
ADMA: ADMA manufactures and markets FDA-approved plasma-derived immune globulin products for immunodeficient and infectious disease patients, operating an integrated plasma collection and fractionation platform. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | ADMA | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $8.48 | $255.43 | |
| Market cap as of 2026-07-30 | $2.0B | $16.1B | |
| P/E as of 2026-07-30 | 12.32 | 546.59 | ADMA lower |
| PEG as of 2026-07-30 | n/a | 58.02 | |
| Net margin as of 2026-07-30 | +32.4% | +0.7% | ADMA higher |
| Gross margin as of 2026-07-30 | +61.3% | +88.0% | JAZZ higher |
| Operating margin as of 2026-07-30 | +41.5% | -0.8% | ADMA higher |
| ROE as of 2026-07-30 | +39.0% | +0.7% | ADMA higher |
| ROA as of 2026-07-30 | +27.4% | +0.3% | ADMA higher |
| Debt / equity as of 2026-07-30 | 0.50 | 1.18 | ADMA lower |
| Revenue growth (YoY) as of 2026-07-30 | +11.0% | +9.2% | ADMA higher |
| Revenue CAGR (3y) SEC XBRL | +49.0% | +5.3% | ADMA higher |
| Beta as of 2026-07-30 | 0.79 | 0.37 | |
| 1-year return as of 2026-07-27 close | -52.9% | +116.0% | JAZZ higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.